BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 27013539)

  • 1. Subtype-Specific Interactions and Prognosis in Cardiac Amyloidosis.
    Sperry BW; Vranian MN; Hachamovitch R; Joshi H; Ikram A; Phelan D; Hanna M
    J Am Heart Assoc; 2016 Mar; 5(3):e002877. PubMed ID: 27013539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic implication of relative regional strain ratio in cardiac amyloidosis.
    Senapati A; Sperry BW; Grodin JL; Kusunose K; Thavendiranathan P; Jaber W; Collier P; Hanna M; Popovic ZB; Phelan D
    Heart; 2016 May; 102(10):748-54. PubMed ID: 26830665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac Structural and Functional Consequences of Amyloid Deposition by Cardiac Magnetic Resonance and Echocardiography and Their Prognostic Roles.
    Knight DS; Zumbo G; Barcella W; Steeden JA; Muthurangu V; Martinez-Naharro A; Treibel TA; Abdel-Gadir A; Bulluck H; Kotecha T; Francis R; Rezk T; Quarta CC; Whelan CJ; Lachmann HJ; Wechalekar AD; Gillmore JD; Moon JC; Hawkins PN; Fontana M
    JACC Cardiovasc Imaging; 2019 May; 12(5):823-833. PubMed ID: 29680336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Noninvasive risk stratification of patients with transthyretin amyloidosis.
    Kristen AV; Scherer K; Buss S; aus dem Siepen F; Haufe S; Bauer R; Hinderhofer K; Giannitsis E; Hardt S; Haberkorn U; Katus HA; Steen H
    JACC Cardiovasc Imaging; 2014 May; 7(5):502-10. PubMed ID: 24726252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of survival stratification in patients with wild-type cardiac amyloidosis.
    Siepen FAD; Bauer R; Voss A; Hein S; Aurich M; Riffel J; Mereles D; Röcken C; Buss SJ; Katus HA; Kristen AV
    Clin Res Cardiol; 2018 Feb; 107(2):158-169. PubMed ID: 28956153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indexed left ventricular mass to QRS voltage ratio is associated with heart failure hospitalizations in patients with cardiac amyloidosis.
    Slivnick JA; Wallner AL; Vallakati A; Truong VT; Mazur W; Elamin MB; Tong MS; Raman SV; Zareba KM
    Int J Cardiovasc Imaging; 2021 Mar; 37(3):1043-1051. PubMed ID: 33068247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac amyloidosis: updates in diagnosis and management.
    Mohty D; Damy T; Cosnay P; Echahidi N; Casset-Senon D; Virot P; Jaccard A
    Arch Cardiovasc Dis; 2013 Oct; 106(10):528-40. PubMed ID: 24070600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis.
    Quarta CC; Solomon SD; Uraizee I; Kruger J; Longhi S; Ferlito M; Gagliardi C; Milandri A; Rapezzi C; Falk RH
    Circulation; 2014 May; 129(18):1840-9. PubMed ID: 24563469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable.
    Rubin J; Maurer MS
    Annu Rev Med; 2020 Jan; 71():203-219. PubMed ID: 31986086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin: Transthyretin Cardiac Amyloid Study (TRACS).
    Bhuiyan T; Helmke S; Patel AR; Ruberg FL; Packman J; Cheung K; Grogan D; Maurer MS
    Circ Heart Fail; 2011 Mar; 4(2):121-8. PubMed ID: 21191093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognosis of Light Chain Amyloidosis With Preserved LVEF: Added Value of 2D Speckle-Tracking Echocardiography to the Current Prognostic Staging System.
    Barros-Gomes S; Williams B; Nhola LF; Grogan M; Maalouf JF; Dispenzieri A; Pellikka PA; Villarraga HR
    JACC Cardiovasc Imaging; 2017 Apr; 10(4):398-407. PubMed ID: 27639764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amyloid cardiomyopathy in a large integrated health care system.
    Czobor P; Hung YY; Baer D; McGlothlin D; Weisshaar D; Zaroff J
    Am Heart J; 2019 Oct; 216():42-52. PubMed ID: 31401442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis.
    Rapezzi C; Quarta CC; Guidalotti PL; Pettinato C; Fanti S; Leone O; Ferlini A; Longhi S; Lorenzini M; Reggiani LB; Gagliardi C; Gallo P; Villani C; Salvi F
    JACC Cardiovasc Imaging; 2011 Jun; 4(6):659-70. PubMed ID: 21679902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transthyretin cardiac amyloidosis: A treatable form of heart failure with a preserved ejection fraction.
    Griffin JM; Maurer MS
    Trends Cardiovasc Med; 2021 Jan; 31(1):59-66. PubMed ID: 31889610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel risk score to predict survival in advanced heart failure due to cardiac amyloidosis.
    Kreusser MM; Volz MJ; Knop B; Ehlermann P; Schmack B; Ruhparwar A; Hegenbart U; Schönland SO; Katus HA; Raake PW
    Clin Res Cardiol; 2020 Jun; 109(6):700-713. PubMed ID: 31630214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue mapping by cardiac magnetic resonance imaging for the prognostication of cardiac amyloidosis: A systematic review and meta-analysis.
    Cai S; Haghbayan H; Chan KKW; Deva DP; Jimenez-Juan L; Connelly KA; Ng MY; Yan RT; Yan AT
    Int J Cardiol; 2024 May; 403():131892. PubMed ID: 38382853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac Amyloid Load: A Prognostic and Predictive Biomarker in Patients With Light-Chain Amyloidosis.
    Kristen AV; Brokbals E; Aus dem Siepen F; Bauer R; Hein S; Aurich M; Riffel J; Behrens HM; Krüger S; Schirmacher P; Katus HA; Röcken C
    J Am Coll Cardiol; 2016 Jul; 68(1):13-24. PubMed ID: 27364045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnetic Resonance in Transthyretin Cardiac Amyloidosis.
    Martinez-Naharro A; Treibel TA; Abdel-Gadir A; Bulluck H; Zumbo G; Knight DS; Kotecha T; Francis R; Hutt DF; Rezk T; Rosmini S; Quarta CC; Whelan CJ; Kellman P; Gillmore JD; Moon JC; Hawkins PN; Fontana M
    J Am Coll Cardiol; 2017 Jul; 70(4):466-477. PubMed ID: 28728692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multi-modal diagnostic model improves detection of cardiac amyloidosis among patients with diagnostic confirmation by cardiac biopsy.
    Zhang KW; Zhang R; Deych E; Stockerl-Goldstein KE; Gorcsan J; Lenihan DJ
    Am Heart J; 2021 Feb; 232():137-145. PubMed ID: 33212046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model.
    Arvanitis M; Koch CM; Chan GG; Torres-Arancivia C; LaValley MP; Jacobson DR; Berk JL; Connors LH; Ruberg FL
    JAMA Cardiol; 2017 Mar; 2(3):305-313. PubMed ID: 28196196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.